Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis

Mitsuyo Yoshida1, Ayumi Taguchi1, Kei Kawana1

  • 1Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

Plos One
|August 3, 2016
PubMed

Insights

Oncogenes like c-MYC and KRAS accelerate ovarian cancer progression by altering the tumor microenvironment (TME). KRAS promotes ascites and inflammation, while c-MYC increases VEGF, impacting tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Oncogenes typically drive cell proliferation and inhibit apoptosis, leading to tumor formation.
  • The impact of oncogenes on the tumor microenvironment (TME) is not fully understood.
  • Ovarian cancer progression involves ascites, inflammation, and elevated VEGF.

Purpose of the Study:

  • To investigate how oncogenes (c-MYC, KRAS) modulate the ovarian cancer TME.
  • To determine the in vivo effects of oncogene transduction on ovarian cancer progression and ascites formation.
  • To analyze changes in VEGF and inflammatory markers within the TME.

Main Methods:

  • Transduction of c-MYC and KRAS into the ID8 mouse ovarian cancer cell line.
  • Injection of modified ID8 cells into C57/BL6 mice to assess tumor progression and ascites production.
  • Measurement of VEGF and inflammatory cytokines in ascites; cytokine array analysis.

Main Results:

  • Both ID8-c-MYC and ID8-KRAS accelerated ovarian cancer progression in vivo, with no significant difference in vitro proliferation.
  • ID8-KRAS induced rapid ascites accumulation (2-3 weeks) compared to ID8-c-MYC (6-7 weeks) and ID8 (9-10 weeks).
  • c-MYC elevated VEGF in ascites; KRAS increased inflammatory cytokines and neutrophils, notably granulocyte macrophage colony-stimulating factor (GM-CSF).

Conclusions:

  • Oncogenes promote ovarian cancer progression by actively reshaping the tumor microenvironment.
  • KRAS and c-MYC utilize distinct TME-modulating mechanisms, influencing ascites, inflammation, and VEGF levels.
  • Targeting oncogene-driven TME alterations could offer new therapeutic strategies for ovarian cancer.